An announcement from Pacira Pharmaceuticals (PCRX) is now available.
Charles A. Reinhart, the CFO of the Company, has agreed to leave the firm by the end of September 2024. The Company is actively looking for his successor and has arranged a generous departure package for Reinhart, including salary continuation, bonus eligibility, immediate vesting of certain stock options, and extended health benefits. Additionally, he will serve in a consultancy role to aid the transition until mid-2025. This move was disclosed alongside the Company’s announcement of its financial results for the previous year.
For a thorough assessment of PCRX stock, go to TipRanks’ Stock Analysis page.
